Home › Funds › Siren, L.L.C. › MNPR
Siren, L.L.C. position in MNPR
Monopar Therapeutics Inc. · Health Care
Siren, L.L.C. reported holding 270,118 shares of MNPR (Monopar Therapeutics Inc.) in its Q3 2026 13F filing — a position valued at US$21.5M, representing 0.51% of its reported portfolio and ranking #48 among its reported holdings. Siren, L.L.C. has disclosed MNPR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s MNPR position evolved
Siren, L.L.C. first disclosed a stake in MNPR in Q4 2025 at 212,298 shares (US$13.9M). The position peaked in Q2 2026 at 270,118 shares, worth US$25.0M. Across 4 filings, Siren, L.L.C. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 270,118 shares valued at US$21.5M. Notable position changes include a 27% increase in Q1 2026 (shares rose 69% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 212.30K | $13.86M | New |
| Q1 2026 | 270.12K | $14.80M | Add |
| Q2 2026 | 270.12K | $25.01M | Hold |
| Q3 2026 | 270.12K | $21.52M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MNPR and 13F data
MNPR (Monopar Therapeutics Inc.) is a Health Care company. 80 other funds we track also report a position in MNPR — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$61.8M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$30.0M), Saturn V Capital Management LP (US$28.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MNPR
- RA CAPITAL MANAGEMENT, L.P. 667.21K sh · $61.78M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 323.75K sh · $29.98M · Q2 2026
- Saturn V Capital Management LP 311.98K sh · $28.89M · Q2 2026
- ADAR1 Capital Management, LLC 217.59K sh · $20.15M · Q2 2026
- TCG Crossover Management, LLC 203.33K sh · $18.83M · Q2 2026
- Vivo Capital, LLC 90.50K sh · $8.38M · Q2 2026
- Ikarian Capital, LLC 47.86K sh · $4.43M · Q2 2026
- STEMPOINT CAPITAL LP 30.12K sh · $2.79M · Q2 2026
- Ishara Investments LP 12.30K sh · $1.14M · Q2 2026
- Martin Investment Management, LLC 2.33K sh · $215.46K · Q2 2026
More on Siren, L.L.C.
FAQ
How long has Siren, L.L.C. held MNPR?
Siren, L.L.C. has disclosed MNPR holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Siren, L.L.C.'s current position in MNPR?
As of Q3 2026, Siren, L.L.C. holds 270.12K shares of MNPR (Monopar Therapeutics Inc.), valued at $21.52M, representing 0.51% of its reported portfolio and ranking #48.
Has Siren, L.L.C. been buying or selling MNPR?
In the latest 13F filing (Q3 2026), Siren, L.L.C. held unchanged its position in MNPR. The position peaked in Q2 2026 at 270.12K shares.
Which other funds hold MNPR?
Other major institutional holders of MNPR include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., Saturn V Capital Management LP, among 80 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.